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Summary The prostate gland is said to be immunologically privileged because it lacks afferent lymphatics
and because of the immunosuppressive properties of seminal fluid. To elicit the presence or absence of an
immune response within the diseased prostate gland, the infiltrate in prostate glands affected by hyperplasia or
adenocarcinoma was phenotypically characterised, using immunohistochemical techniques. An infiltrate, com-
posed mainly of T-lymphocytes (CD-3 +), was demonstrated in all glands examined. No difference in the type,
level of activation or degree of infiltration was found between those glands affected by hyperplasia (n = 20)
and those affected by adenocarcinoma (n = 20). In the malignant cases, there was no correlation between grade
(Gleason) or stage (TNM) and the type or degree of mononuclear cell infiltrate. Our findings suggest that the
host response, in situ, to hyperplasia and adenocarcinoma is similar and may reflect the fact that the two
diseases are often found concurrently in the same gland and in close proximity to one another. The infiltrate,
therefore, is unlikely to represent a tumour specific immune response to tumour specific antigens. The
significant infiltrate we have demonstrated, and its phenotypic characterisation, would not support the
hypothesis that the prostate is immunologically privileged as has been suggested previously.
It has been estimated that the majority of men over 60 years
will have some degree of prostatic hyperplasia. Likewise,
malignant prostatic disease, rare before 50 years, shows a
rapidly increasing incidence in the later decades. Latent foci
of incidental adenocarcinoma can be found, according to
some estimates, in over 40% of prostate glands of men aged
75 years (Halpert & Schmalhorst, 1966); most of these fail to
cause any morbidity. The prostate is unique in having this
very high incidence of occult foci of carcinoma.
The diseased prostate gland, whether affected by hyper-
plasia or adenocarcinoma, is often noted on routine histo-
logical examination to have a variable inflammatory
infiltrate. This has usually been assumed in the past, in the
absence of relevant bacteriological examination, to be secon-
dary to chronic infection in the prostatic tissue. The presence
of an inflammatory infiltrate, however, is well documented in
malignant disease involving various organs and is said to
represent a host immune response to the tumour (Vose &
Moore, 1985). Recently, the lymphocytic infiltrate in the
normal prostate gland has been characterised (El-Demiry et
al., 1985). The infiltrate in the diseased gland, on the other
hand, has been poorly characterised (Shaw et al., 1983) and,
to the best of our knowledge, the cells within this infiltrate
have not been previously examined in situ.
In order to more fully document this mononuclear cell
infiltrate we have used cell surface specific monoclonal
antibodies to analyse both the type and distribution of these
different cell subsets, particularly as regards their relationship
to diseased prostatic tissue. In addition, we have used
antibodies reactive with the interleukin-2 receptor and HLA-
DR antigens to assess the degree of activation of these
infiltrating cells.
Materials and methods
Patients
Written consent was obtained from all patients entered in the
study.
Prostatic hyperplasia
Twenty patients admitted for routine surgery with presumed
prostatic hyperplasia were selected. The mean age was 70
years (range 52-88 years).
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Prostatic adenocarcinoma
Twenty patients with preoperative evidence of adenocar-
cinoma (i.e. a clinically suspicious gland and/or a
biochemical abnormality such as a raised prostatic acid phos-
phatase and/or prostatic specific antigen) were entered in the
study. All patients were clinically staged using the TNM
system (Figure 1). The mean age was 74 years (range 60-86
years). The two groups were comparable with regard to age
with no significant difference between the groups (X2 test,
P> 0.5).
Prostatic tissue specimens
Fresh tissue was obtained at the time of transurethral pros-
tatic resection. The prostatic chips were snap-frozen and
6-8gm thick frozen sections were then cut. The sections
were allowed to air-dry at room temperature overnight
before staining. All sections were stained within 48 h of
resection.
All prostatic adenocarcinoma cases were examined by two
observers and the degree of differentiation graded using the
Gleason grading method (Gleason, 1966, 1977). This gave a
score (between 2 and 10) and the cases were then placed into
three standard grades (grade 1, 2-5; grade 2, 6-7; and grade
3, 8-10) (Figure 1).
Monoclonal antibodies
The panel of monoclonal antibodies used is shown in Table
I. The specificities of these antibodies have been well de-
scribed previously.
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Figure I T stage and Gleason grades of tumour specimens.
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Table I Monoclonal antibody panel
Monoclonal antibody Specificity
CD-3 (Leu 4) Pan T-lymphocytes
CD-4 (Leu 3a) Helper/inducer T-lymphocytes
CD-8 (Leu 2a) Cytotoxic/suppressor T-lymphocytes
CD-22 (Leu 14) Pan B-lymphocytes
CD-16 (Leu 7 & lb) Natural killer cells
CD-I Ic (Leu M5) Monocytes and macrophages
CD-25 (IL-2R)a Interleukin-2 receptor
HLA-DRb Activated T-lymphocytes and macrophages
'Dakopatts A/C; bScottish Antibody Production Unit; all others
obtained from Becton-Dickinson.
Immunohistochemical procedure
The monoclonal antibodies were reacted with immune com-
plexes of alkaline phosphatase and monoclonal anti-alkaline
phosphatase (APAAP complexes) (Cordell et al., 1984). The
sections were fixed in acetone before staining and then
washed in 0.05 M, pH 7.6, Tris-buffered saline (TBS). The
monoclonal antibody was applied, at optimal dilution, for
I h. The sections were then incubated with rabbit anti-mouse
immunoglobulin for 30 min followed by incubation with
APAAP complexes for 30 min. The sections were washed
three times with TBS between incubations. The sections were
developed with a veronal acetate buffer solution (VAB) con-
taining Napthol AS-MX phosphate and Fast Red TR, with
levamisole added to inhibit endogenous alkaline phosphatase
(Ponder & Wilkinson, 1981). The sections were counter-
stained in Mayer's haematoxylin. Negative controls included
sections in which the primary antibody was omitted. Positive
controls were carried out on human lymph node sections to
check antibody reactivity and to determine optimal dilutions
of antibody. Routine haematoxylin-eosin sections were also
prepared in each case and the histological appearances
reviewed with a pathologist (I.D.M.).
Examination ofspecimens andscoring
The sequential sections were examined by light microscopy
and the total number of positive cells in 20 random, conse-
cutive, high power fields was counted (total area = 1.2 mm2).
The relative distribution of positive cells between the
epithelial tissue and the interstitial fibromuscular tissue was
also recorded. Positive luminal lymphoid cells were included
in the epithelial counts as were all positive cells among the
acinar epithelium. All other positive cells were counted as
interstitial. In high grade tumours, where interstitial tissue
was very sparse among sheets of tumour cells, positive cells
were counted as being in epithelial tissue (see Figure 2) unless
they were in the interstitial tissue found between the sheets of
tumour cells.
From these counts we were able to determine the follow-
Figure 2 T-lymphocytes (CD-3 +) in high grade prostatic car-
cinoma; note the paucity of distinct interstitial tissue (APAAP
technique).
ing: (i) the relative ratios of T cells, B cells and macrophages
in the prostate; (ii) the distribution pattern of the various
cells in the two compartments of the gland; and (iii) the ratio
of T cell subsets within the prostate.
Results
Prostatic hyperplasia
The 20 cases of hyperplasia showed typical morphology and
an inflammatory infiltrate was present in all cases. This
ranged from a diffuse infiltrate to intense periglandular col-
lections and was of varying intensity (Figure 3). Most of the
infiltrating cells were T-lymphocytes (CD-3 +) (Table II) and
the majority were found in the periglandular stromal tissue.
Prostatic adenocarcinoma
As with benign disease the main infiltrating cell was the
T-lymphocyte (Table II and Figure 4). There was no
significant difference in the percentages of major cell types
found in hyperplasia and adenocarcinoma (P> 0.5, X2).
There was also no correlation between T stage and/or
Gleason grade and the degree or type of infiltrate found. The
distribution of T stage and Gleason grades is shown in
Figure 1.
Overall
There was no difference in the degree or type of infiltrate
between benign and malignant disease. T-lymphocyte activa-
tion, as assessed by the number of cells expressing IL-2
receptors (15-20%), also showed no statistically significant
difference between the two disease processes (P> 0.1, Wil-
coxon). Expression of IL-2R (CD-25) is used as a marker of
recent activation (Greene & Leonard, 1986; Waldmann,
1986). Many of these cells also expressed HLA-DR antigen
as did a large proportion of the macrophages.
The stromal CD-4/CD-8 ratio in hyperplasia and
adenocarcinoma was significantly different (P = 0.002, Wil-
coxon) but the overall ratio of helper/inducer (CD-4 +) to
cytotoxic/suppressor (CD-8 +) cells was similar in both
disease processes. There was a significant difference in the
subset distribution between the epithelial and stromal com-
Figure 3 Diffuse infiltrate of T-lymphocytes (CD-3 +) in pros-
tatic hyperplasia showing variation in intensity of infiltrate
(APAAP technique; bar = 20glm).
Table II Percentages of major cell types within the inflammatory
infiltrate
T-bymphocytes B-lymphocytes Macrophages
(CD-3) (CD-22) (CD-iJa)
Hyperplasia 69 2 9 + 2 23 1
Adenocarcinoma 63 ± 2 9 ± 2 27 ± I
Values are means ± s.e.m., n = 20.402 S. MCCLINTON et al.
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Figure 4 T-lymphocytes (CD-3 +) in low grade prostatic car-
cinoma (APAAP technique).
ponents of the gland in both diseases (hyperplasia P = 0.001;
adenocarcinoma P< 0.001, Wilcoxon) with most of the
intra-epithelial infiltrate being composed of T-cytotoxic/
suppressor cells (CD-8 +) (Table III).
Macrophages (CD-1 Ilc +) in quite large numbers (23-27%)
were demonstrated in both disease processes. Natural killer
cells (CD-16+) were rarely seen in either type of diseased
gland. B-lymphocytes (CD-22 +) constituted a small percen-
tage of the total infiltrate (9%). Plasma cells, as assessed by
morphology, were only rarely noted in the sections examined.
Neither hyperplastic nor tumour epithelium, in common with
most normal epithelia, was shown to express HLA-DR
antigens.
Discussion
An inflammatory infiltrate has been demonstrated in many
human solid tumours (Underwood, 1974) and has been pos-
tulated to represent a host anti-tumour response (Vose &
Moore, 1985; loachim, 1976). The composition of this
infiltrate is variable, with some tumours containing large
numbers of macrophages, but in most tumours the main
infiltrating cell is the T-lymphocyte. A correlation between
the presence and type of intratumoral infiltrate and prognosis
has been suggested for many tumours; an improvement in
prognosis in most tumours (Mostofi & Sesterhenn, 1976;
Haskill, 1982) although the converse has been demonstrated
(Steele et al., 1984). Indeed, experimental tumour models
have shown that infiltrating host cells can have a tumour
promoting effect (Evans, 1978).
The inflammatory infiltrate within the diseased prostate
gland has not been previously characterised. The majority of
the infiltrating cells were CD-3 positive T-lymphocytes
(hyperplasia 69%; adenocarcinoma 63%) with a significant
difference in the distribution pattern of the T-lymphocyte
subsets between epithelial and stromal tissues. This micro-
anatomical pattern is also seen in normal intestine where the
intra-epithelial cells are mainly T-cytotoxic/suppressor cells
while the stromal cells are mainly T-helper/inducer cells
(Selby et al., 1981; Targan, 1987).
Differences in the infiltrate found in benign and malignant
disease have been demonstrated in ovarian and skin neo-
plasms with significantly fewer T-lymphocytes in benign and
borderline epithelial tumours than in their malignant
counterparts (Kabawat et al., 1983; Kernohan & Sewell,
1989). Explanations given for this difference were that it was
possibly due to a better recognition of malignant tumours by
the immune system or a function of tumour necrosis causing
release of chemotactic factors.
Immunological studies in patients with prostatic cancer
have shown some evidence of host responses to tumour. This
is less prominent than that documented in patients with some
other solid tumours. Cell-mediated immunity is depressed in
many prostatic cancer patients, but some patients with
clinically advanced disease exhibit normal cell-mediated
immunity (Catalona, 1980). This has been postulated to be
due to the prostate being a partially immunologically
privileged site (Gittes & McCullough, 1974), the immunosup-
pressive properties of seminal plasma (Ablin et al., 1980;
James & Hargreaves, 1984) and perhaps to tumour-
elaborated factors (Ablin, 1977).
The degree of T-lymphocyte activation, as assessed by
HLA-DR and IL-2 receptor status, was the same in both
benign and malignant prostatic neoplasms. It should be
noted that the two disease processes are often concurrent and
in close proximity, although the anatomical distribution in
the gland has been shown to be different (McNeal, 1969).
The nature of the cellular infiltrate and the level of T-
lymphocyte activation demonstrated is not suggestive of an
active host response to tumour specific antigens. Nor is it in
keeping with the hypothesis that the prostate is in some way
an immunologically privileged site. Also our findings suggest
that the suppressive effects of seminal plasma in situ may not
be profound. Human seminal plasma has been shown to
inhibit significantly IL-2R expression on mitogen stimulated
peripheral blood T-lymphocytes (Quayle et al., 1987). Our
results suggest that the prostatic component of seminal
plasma is probably not inhibitory within the prostate gland.
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Table III T-lymphocyte subset counts and ratios (CD-4 +/CD-8 +): within the two anatomical
compartments of the gland, and overall
Hyperplasia Adenocarcinoma
CD-4 CD-8 CD-4/CD-8 CD-4 CD-8 CD-4/CD-8
Epithelium 22 ± 12 36 ± 14 0.7 ± 0.4a 29 ± 18 52 ± 24 0.6 ± 0.3b
Stroma 76±52 71 ±31 1.1 ±0.5a 42± 15 23±8 2.00.9b,c
Overall 98 ± 63 107 ± 38 0.9 ± 0.4 70 ± 28 76 ± 28 1.0 ± 0.4
Values are means ± s.d., n = 20. By Wilcoxon rank sum test: a,b p< 0.001, c p = 0.002.
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